Multiple endocrine neoplasia type 2A (MEN 2A) and familial medullary thyroid carcinoma (FMTC) are two dominantly inherited disorders caused by germline mutations of the RET proto-oncogene. The RET gene codes for a receptor tyrosine kinase. The majority of MEN2A and FMTC mutations are clustered in the extra-cellular cysteine-rich domain and result in constitutive activation of the tyrosine kinase through the formation of disul®de-bonded RET homodimers. Recently, two novel point mutations have been identi®ed in the germline of ®ve distinct FMTC families. Both mutations occur within the catalytic domain of the RET kinase and lead to the substitution of either glutamic acid 768 or valine 804 by an aspartic acid and a leucine respectively. We have introduced each FMTC mutation in two RET isoforms: RET51 the long isoform (1114 aa) and RET9 the short isoform (1072 aa) which dier in the C-terminal region of the protein. The RET51 isoform carrying either E768D or V804L mutation was autophosphorylated, displayed a transforming activity upon expression in Rat1 ®broblasts and induced neuronal dierentiation of PC12 cells. However, the transforming capacity of these RET51-FMTC mutants was found to be severalfold less potent compared to the same isoform carrying either the MEN2A mutation (C634R) or the MEN2B mutation (M918T). In contrast, RET9 containing mutations E768D or V804L was not autophosphorylated, exhibited a poor oncogenic potential in ®broblasts and did not promote neuritic outgrowth upon expression in PC12 cells.
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Introduction
Germline mutations of the RET proto-oncogene cause a dominantly-inherited cancer syndrome: the multiple endocrine neoplasia type 2 (MEN 2) (reviewed in Goodfellow, 1994; Mulligan and Ponder, 1995; Pasini et al., 1996) . MEN 2 comprises three related disorders. MEN type 2A (MEN 2A) is characterized by the association of medullary thyroid carcinoma, a malignant tumour of the calcitonin-secreting thyroid C-cells, pheochromocytomas, and hyperparathyroidism. In familial MTC (FMTC), the thyroid cancer is the sole clinical manifestation. Patients aected by the rarer third type of MEN 2 referred as MEN type 2B (MEN 2B) present a complex disease phenotype with association of MTC, pheochromocytoma and developmental abnormalities including mucosal neuromas, ganglioneuromatosis of the digestive tract and marfanoid habitus (Goodfellow, 1994; Mulligan and Ponder, 1995; Pasini et al., 1996) .
The RET gene codes for a receptor tyrosine kinase (Takahashi et al., 1988) which possesses a cadherin-like domain (Schneider, 1992) and a cysteine-rich motif in its extracellular region. Recently, it has been shown that RET is a component of a cell-surface protein complex which functions as a receptor for a neurotrophin called GDNF (Glial cell-line Derived Neurotrophic Factor) (Durbec et al., 1996; Jing et al., 1996; Treanor et al., 1996; Trupp et al., 1996) . Several RET isoforms which dier in the extra-cytoplasmic domain and in the carboxy-termini are encoded by alternatively-spliced transcripts (Tahira et al., 1990; Lorenzo et al., 1995; Myers et al., 1995) . Although the function of the RET proteins is not yet known, the lack of kidneys and intestinal ganglion nerve cells in mice homozygous for a disruptive mutation in the RET gene suggests that RET function is critical for renal development and enteric neurogenesis (Schuchardt et al., 1994) .
Germline mutations of the RET gene are the underlying cause of the majority of MEN 2 cases (reviewed in Goodfellow, 1994; Mulligan and Ponder, 1995; Pasini et al., 1996) . Previous reports have established that the nature and the position of the RET mutations correlate with the three MEN 2 clinical phenotypes. In MEN 2A and FMTC, mutations in the germline of aected individuals are located in the sequence encoding the juxtamembrane cysteine-rich domain. These mutations involve amino acids C609, C611, C618, C620 and C634 and result in the substitution of the cysteine for a dierent amino acid (Donis- Keller et al., 1993; Mulligan et al., 1993 Mulligan et al., , 1994 Schuenecker et al., 1994) . Mutations at one of these ®ve cysteines have been found in 98% of the MEN 2A families and in 88% of FMTC (Eng et al., 1996) . Furthermore, MEN 2A is predominantly associated with a mutation of C634 (Donis- Keller et al., 1993; Mulligan et al., 1994; Schuenecker et al., 1994; Eng et al., 1996) . This mutation, which involves the cysteine nearest to the transmembrane domain, is highly predictive for the development of pheochromocytomas and hyperparathyroidism Schuenecker et al., 1994) . The unique mutation known to cause MEN 2B, and detected in 95% of cases, is a single point mutation which leads to the substitution of methionine 918 for a threonine within the tyrosine kinase domain (Carlson et al., 1994; Eng et al., , 1996 Hofstra et al., 1994; Rossel et al., 1995) . The fact that the chromosome 10 allele is not lost and that the wild-type and mutated RET alleles are coexpressed in MEN 2-associated tumours, supports the notion that MEN2 mutations transform the RET protein into a dominantly-acting oncogene. This model has recently been supported by the demonstration that RET protein carrying MEN2 mutations has transforming activity (Asai et al., 1995; Borrello et al., 1995; Santoro et al., 1995; Rossel et al., 1997) . In particular, MEN2A/FMTC mutations cause a ligand-independent dimerization of RET via the formation of disul®de-linked homodimers (Asai et al., 1995; Santoro et al., 1995) , while the MEN2B mutation appears to change the substrate speci®city of the tyrosine kinase (Santoro et al., 1995; Songyang et al., 1995; Liu et al., 1996) .
Recently, we and others have reported the detection of two missense mutations that aect either amino acids E768 or V804 in ®ve independent FMTC families Bolino et al., 1995) . These two mutations change glutamate 768 and valine 804 which are both located in the tyrosine kinase domain for an aspartate and a leucine respectively. We now report that these two FMTC mutations are gain of function mutations and result in aberrant signalling mediated by RET. It appears however that these mutations are more weakly activating than MEN2A and MEN2B mutations, a ®nding which might account for the disease phenotype which is only associated with thyroid neoplasia.
Results
The transforming ability of RET with FMTC mutations aecting the tyrosine kinase domain is isoform speci®c Three RET isoforms containing 1114, 1106 and 1072 amino acids (referred as RET9, RET43 and RET51) which dier in the carboxy-termini have been characterized (Tahira et al., 1990; Myers et al., 1995) . Based upon RNA studies, it appears that the transcripts coding for RET9 and RET51 are more abundant in MEN 2-associated tumours than mRNAs coding for the other RET isoform ; LF and MB, data not shown). We and others have recently found that RET51 and RET9 carrying MEN 2 mutations displayed dierent biological eects in ®broblasts and in pheochromocytoma PC12 cells Rossel et al., 1997) . Therefore, to address the consequences on RET function of the two FMTC mutations involving the tyrosine kinase domain (E768D and V804L) we mutated the cDNAs coding for the human RET9 and RET51 isoforms accordingly (Figure 1) . In order to compare the biological eects of these two FMTC mutations with MEN2A and MEN2B mutations, we also engineered constructs in which the cDNAs coding for RET9 and RET51 were mutagenized at codon 634 (C634R) and codon 918 (M918T) (Rossel et al., 1997) . The cDNAs were then cloned into the retroviral vector pBabe-Puro (Morgenstern and Land, 1990) and placed under the control of the Moloney murine leukemia virus (Mo-MuLV) long terminal repeat (LTR). The resulting constructs were transfected into the BOSC 23 packaging cell-line (Pear et al., 1993) to produce ecotropic retroviruses. Rat 1 ®broblasts were infected with retroviruses expressing the various RET alleles, and mass populations of resistant cells were obtained by selection with puromycin. To examine the transforming ability of the FMTC mutant forms of RET, we tested the capacity of Rat 1 cells transduced with RETexpressing retroviruses to grow in semi-solid medium. Rat 1 cells expressing both RET51 or RET9 with mutations E768D or V804L produced colonies in soft agar within 3 weeks from seeding (data not shown). However, the expression of RET9 carrying these two mutations resulted in an extremely low number of colonies, not substantially dierent from background levels obtained with Rat1 expressing wild-type RET9 or RET51. Rat 1 cells expressing RET9 with a MEN2A mutation or with the MEN2B mutation grew in softagar, and colonies were already detectable within one week (data not shown). We next quanti®ed the transforming potency of various RET-MEN 2 proteins. Results depicted in Table 1 which represent ®ve independent series of experiments, show that the eciency of colony formation obtained with RET51-768D and RET51-804L mutants was 2.5-to 3.5-fold lower than RET51-634R or RET51-918T. Taken together, these results establish that both FMTC mutations aecting the tyrosine kinase domain convert RET51 into a dominantly-acting oncogene. However, Figure 1 Schematic representation of the two RET isoforms considered in this study. The long (1114 amino acids) and the short (1072 amino acids) isoforms dier in their carboxy-terminal region and are here referred to as RET51 and RET9, respectively. The nature and position of the MEN 2A (C634R), FMTC (E768D; V804L) and MEN 2B (M918T) mutations employed in this study are depicted 
Number of colonies
Transforming capacity evaluated as the growth in soft agar of Rat 1 ®broblasts stably expressing wild type RET isoforms and RET-MEN 2 mutants. Rat1 cells were seeded in soft agar in triplicate and colonies were counted 3 weeks after plating. (a) and (e) represent 50 mm the extremely weak oncogenic potential of RET9 carrying mutations E768D or V804L diers from the signi®cant transforming properties of this RET isoform activated by MEN2A and MEN2B mutations.
The long RET isoform altered by FMTC mutations aecting the tyrosine kinase domain induces neuronal dierentiation of PC12 cells
We and others have previously shown that expression of RET9 and RET51 with MEN2A and MEN2B mutations triggers neuronal dierentiation of rat pheochromocytoma PC12 cells, as manifested by the extension of long neuritic processes and cessation of cell division (Borrello et al., 1995; Califano et al., 1996; Rossel et al., 1997) . To analyse the biological activity of RET isoforms with mutations E768D or V804L, we infected PC12 cells with MFG retroviruses (Drano et al., 1993) carrying RET mutant alleles, taking care to equate the number of infectious particles for each infection. Expression of RET51-768D or RET51-804L in PC12 cells elicited neurite outgrowth (Figure 2c and d). The time course of neurite extension paralleled that observed with RET51 carrying C634R or M918T mutations. Neurite elaboration was detectable at 48 h, peaked at 96 h and was resorbed within 196 h (data not shown). Conversely, expression of RET9-768D or RET9-804L mutants was not followed by a change of PC12 cell morphology (Figure 2g and h).
The same result was obtained even when the retroviral inoculum was increased by threefold (data not shown). These results con®rm that the short and long RET isoforms display contrasting biological activities when activated by FMTC mutations aecting the tyrosine kinase domain.
Eect of FMTC mutations on RET tyrosine kinase activity
To explore whether mutations E768D and V804L lead to a ligand-independent activation of the RET tyrosine kinase, we ®rst measured the level of RET autophosphorylation in vivo. Lysates of NIH3T3 cells stablyexpressing dierent forms of RET were subjected to immunoprecipitation with the anti-RET serum and the resulting samples were analysed by Western blotting using the anti-RET antibody. Two RET species of 150 kDa and 170 kDa which respectively correspond to an incompletely glycosylated precursor and to the fully mature protein present at the cell surface (Taniguchi et al., 1991; Asai et al., 1995) were identi®ed (Figure 3a and c). The antibodies were subsequently stripped from the membrane and the ®lter was analysed with an anti-phosphotyrosine monoclonal antibody (4G10). Both RET51-E768D and RET51-V804L mutant proteins displayed a similar increase in the level of tyrosine phosphorylation when compared to wild-type RET51 (Figure 3b ). Both RET9-FMTC mutants showed no apparent increase in tyrosine phosphorylation in comparison to their wild-type counterpart (Figure 3d ). To further compare the biochemical properties of the two RET isoforms carrying FMTC mutations, we analysed their ability to phosphorylate bona ®de substrates. It has been recently shown that the binding of the Shc adaptor protein to RET-MEN 2 is a key early event in the transduction of the mitogenic signal (van Weering et al., 1995; OG and MB, manuscript in preparation) . The Shc protein was immunoprecipitated from NIH3T3 cells expressing at comparable levels the various RET proteins and the immunoprecipitates were analysed by Western blot techniques. Figure 4a and 4b shows that the three proteins of 52 kDa and 46 kDa and to a lesser extent 66 kDa, which correspond to the three Shc isoforms, had high tyrosine phosphorylation levels when acted upon by RET51 carrying the E768D and V804L mutations, but RET9 bearing the same mutations gave lower phosphorylation levels. However, expression of RET9 bearing the C634R mutation or the M918T mutation in NIH3T3 cells, led to a signi®cant increase in the tyrosine phosphorylation content of Shc ( Figure  4b ).
To substantiate our observation that the two FMTC mutations E768D and V804L lead to the ligandindependent activation of RET tyrosine kinase function we performed an in vitro immune complex kinase assay, using Myelin Basic Protein (MBP) as an exogenous substrate. Surprisingly, both RET isoforms mutated at codon 768 or 804 displayed a comparable enhancement in both their autokinase activity and their ability to phosphorylate MBP (Figure 5a and b) . Quanti®cation of the 32 P-labelled bands showed that the autophosphorylation activity as well as the kinase activity towards MBP of the RET-FMTC (E768D; V804L) and RET-MEN 2A (C634R) proteins were comparable regardless of the isoform expressed and were about three-fold stronger than those of the wildtype counterparts. Consistent with previous reports (Borrello et al., 1995; Rossel et al., 1997) , the RET-MEN 2B (M918T) mutants showed a limited increase in their kinase activity towards MBP (1.5-fold) and no increase in the autokinase activity.
Discussion
Germline mutations in the sequence coding for two distinct domains of the RET protein, i.e. the cysteinerich region and the tyrosine kinase domain, are associated with FMTC (reviewed in Goodfellow, 1994; Mulligan and Ponder, 1995; Pasini et al., 1996) . It is now well established that mutations aecting any one of ®ve cysteines of the cysteine-rich region result in a constitutive activation of the tyrosine kinase via the formation of covalently-linked RET homodimers (Asai et al., 1995; Santoro et al., 1995) . In the present study we have further investigated the consequences of FMTC mutations on RET function and demonstrated that the long RET isoform carrying either mutation E768D or mutation V804L, both located in the tyrosine kinase domain, is transforming in ®broblasts and induces dierentiation of pheochromocytoma PC12 cells. These biological eects are due to the ligand-independent stimulation of the tyrosine kinase activity. However, these two RET mutants are two-to three-fold less transforming than the same RET isoform carrying a MEN2A or the MEN2B mutation. Strikingly, the short RET isoform containing either the E768D or the V804L substitution exhibited a very weak oncogenic eect in Rat1 ®broblasts and did not promote neurite outgrowth upon expression in PC12 cells. This inability to give rise to a phenotype re¯ected the lack of autokinase activity as manifested by the absence of steady-state tyrosine phosphorylation. Taken together, these data provide compelling evidence that these two FMTC mutations, like MEN2A and MEN2B mutations, result in RET receptor activation, but also pinpoint unanticipated dierences between these mutants.
One surprising outcome of our work is the contrasting potency between the two RET splice variants carrying FMTC mutations. The long RET isoform displays two additional tyrosines of which one (Tyr-1096) is an autophosphorylation site and can serve as a docking site for Grb2 (Liu et al., 1996) . Owing to the capacity of Grb2 to recruit son of sevenless (Sos) and to stimulate the Sos-mediated GDP for GTP exchange on Ras (reviewed in van der Geer et al., 1994; Pawson, 1995) it is conceivable that this interaction of Grb2 with RET51-768D or RET51-804L might potentiate the activation of the Ras pathway, thus resulting in an increased transforming ability. Mutagenesis of Tyr-1096 in RET51 containing FMTC However, Grb2 can also be indirectly linked to RET and exert its eect on the Ras cascade through its binding to the tyrosine-phosphorylated form of Shc, an adaptor protein consisting of an N-terminal phosphotyrosine-binding domain (PTB) and a C-terminal SH2 domain (Bon®ni et al., 1996) . Tyr-1062, a residue shared by the long and short RET isoforms is a major binding site for Shc and mutation of this tyrosine ablates the oncogenic activity of RET MEN 2 mutants OG and MB, manuscript in preparation) . Furthermore, it appears that the phosphorylation of Shc depends on its interaction with the phosphorylated-tyrosine 1062 of RET OG and MB, manuscript in preparation) . In NIH3T3 cells stably-expressing RET51-768D or RET51-804L, the 46 kDa and 52 kDa and to a lesser extent the 66 kDa Shc species were found to be tyrosine phosphorylated, whereas the level of phosphorylation of Shc isoforms was barely above background in cells expressing the short RET variant with FMTC mutations. These data suggest that RET51-768D and RET51-804L proteins, but not the RET9 counterparts are capable of autophosphorylating Tyr-1062. One model which might account for this ®nding postulates that the C-terminal region speci®c to RET51 might modify the overall conformation of the tyrosine kinase domain and enhance the catalytic activity. Alternatively, it is possible that the 51 amino acids of the long RET isoform, and not the 9 amino acids of the short RET isoform, facilitate the transient dimerization of RET or stabilize the short-lived dimeric form of RET which may spontaneously form, thereby permitting substantial trans-auto-phosphorylation of critical tyrosines such as Tyr-1062. This working model might account for the fact that RET9 proteins harbouring mutations E768D or V804L are poorly autophosphorylated while RET9-634R is constitutively activated due to the formation of covalently-linked RET homodimer. Results of the in vitro kinase assay are in favour of the latter hypothesis since we observed that both levels of phosphorylation of RET and MBP obtained with the dierent forms of RET carrying mutations E768D or V804L were similar, regardless of the nature of the isoforms expressed. These ®ndings indicate that the kinase activities of RET9-768D and RET9-804L are comparable with their RET51 counterparts, and further suggest that aggregation of RET9 molecules provoked by the antibodies in the immune complex is a prerequisite step to achieve a signi®cant autophosphorylation.
The X-ray crystal structures of the tyrosine kinase domains of the insulin (IRK) and FGF (FGFR1K) receptors, which have been recently determined (Hubbard et al., 1994; Mohammadi et al., 1996) , provided a template for constructing a model of the RET tyrosine kinase domain (RETK) in order to determine the structural consequences of FMTC mutations. Amino acids 988 ± 1270 from IRK, 470 ± 761 from FGFR1K and 716 ± 1012 from RETK were aligned ( Figure 6) . A model of the catalytic core of RET, based on the crystal structure of IRK was obtained. This model is compatible with the secondary structure and the topology of IRK and FGFR1K, with a similar distribution of the nine b-strands and eight ahelices and the conserved bi-lobate scaold speci®c to the protein kinase catalytic domain (Hubbard et al., 1994; Mohammadi et al., 1996) . As previously noted, E768 is located in the N-terminal segment of a-helix C . However, it is unlikely that the E768D mutation results in weakening a presumed salt bridge with the highly conserved K758 of RETK, as recently proposed , since the distance between these two residues, which is 14 A Ê in our model (14.8 A Ê in IRK) appears to be too great for such an interaction. In FGFR1K the corresponding residue (E524) appears to be properly positioned to form a salt bridge with R645 which lies in the activation loop. Therefore, it can be hypothesized that an interaction between E524 and R645 of FGFR1K and E768 and R897 in RETK might participate in the stabilization of the activation loop in an inhibiting conformation. Consequently, the shortening of the side chain which results from the replacement of the glutamate 768 by an aspartate acid might weaken this interaction, hence shifting the activation loop in a conformation compatible with the binding of substrates. V804 is positioned in the hydrophobic pocket which binds the adenine ring of ATP. Furthermore, the amino acid immediatley following V804 is a glutamic acid conserved at the same position in IRK, FGFR1K (Figure 8 ) and the cyclic AMP-dependent protein kinase (cAPK), and this residue is hydrogen-bonded to the N6 of adenine in FGFR1K (Mohammadi et al., 1996) and cAPK (Zheng et al., 1993) . Spatial positioning of V804 suggests that replacement by a leucine might modify the nucleotide-binding domain of RETK, thus facilitating the access of ATP to the catalytic site. Based on the model, it is also plausible that V804 interacts with the activation loop, however, in this context, the consequences of the FMTC mutation are dicult to interpret.
Mutations at codons 768 and 804 have been identi®ed in the germline of aected members of ®ve independent FMTC kindreds Bolino et al., 1995) . This correlation between genotype and disease phenotype raises an interesting question about the underlying molecular mechanisms which might account for the restricted biological eect of RET-768D or RET-804L (FMTC-associated mutations) in thyroid C-cells. Given the contrasting transforming capacity between the long and short RET isoforms carrying these FMTC mutations, it is plausible that the tissue speci®city mirrors the tissue distribution of the RET isoforms, with RET51 being expressed in C-cells but not or weakly in chroman and parathyroid cells. Alternatively, one might envision that each type of endocrine cell responds to a de®nite quantum of net signal output emanating from RET-MEN 2 receptors. According to this threshold model, C-cells would be the most sensitive to the mitogenic eect of RET, chroman cells being intermediate and parathyroid cells the least responsive . Consequently, the spectrum of aected tissues would correlate with the transforming potential of MEN 2 forms of RET. This working hypothesis ®ts with the biochemical data described herein, since RET51-768D and RET51-804L were found to be signi®cantly less transforming than other RET51-MEN 2 mutants. Furthermore, it is tempting to speculate that, due to the impaired signalling capacity of RET9 with mutations 768 or 804, the pool of RET isoforms capable of triggering the cell cycle is reduced, thus further narrowing the biological eects of these FMTC mutant forms of RET to thyroid C-cells. In this context it is worth noting that the clinical features of patients with a germline mutation at codon 804 and belonging to an extensively studied FMTC family sustained this model. Gene carriers developed small foci of MTC with a low penetrance (Bolino et al., 1995) , thus reinforcing the notion that RET activated by the mutation 804 is a weak oncogene. Although this model fully accounts for the data presented here, it remains to be explained why the mutation at codon 768 is present in 10% of sporadic MTC, whereas mutations at one of the ®ve codons specifying a cysteine are very rarely present in sporadic MTC (reviewed in Mulligan and Ponder, 1995) . The present work was aimed at studying the biological activity of two RET variants, RET9 and RET51, carrying two FMTC mutations. However, it is conceivable that the other RET isoforms recently characterized Myers et al., 1995) might be endowed with biological properties distinct from RET9 and RET51, a question it would be thus relevant to address using the same approach described in this study. Finally, while this work was being completed, a new mutation at codon 804 (Val 804 for Met) was identi®ed in aected members of one FMTC family (Fink et al., 1996) . Future studies should elucidate the biological significance of this new FMTC mutation.
Materials and methods

Construction of vectors and production of ecotropic retroviruses
The cDNAs coding for the two isoforms RET51 and RET9 were cloned as previously described (Rossel et al., 1997) and ligated in the retroviral vectors pBabe Puro (Morgenstern and Land, 1990) and pMFG (Drano et al., 1993) . The U.S.E. Mutagenesis Kit (Pharmacia Biotech) was used to introduce the two mutations E768D and V804L with the following primers: 5'-CTCCCCGAGT-GACCTTCGAGACCTG-3'; 5'-CCGCTCCTCCTCATC-TTGGAGTACGCCAAATAC-3'. Ecotropic retroviruses were obtained by transient transfection of the retroviral vectors into the BOSC 23 packaging cell line according to the protocol described by Pear et al. (1993) . Forty-eight hours after transfection, the supernatants were harvested and ®ltered on 0.45 mm pore size ®lters. Titers of the Babe Puro viral stocks were determined by infecting NIH3T3 cells in presence of 8 mg/ml of polybrene. Forty-eight hours after infection the cells were split 1 : 10 into medium containing 2 mg/ml puromycin. Puromycin resistant colonies were stained with Giemsa and counted on day 15. Retroviral titers were routinely comprised between 5610 5 and 1610 6 colony-forming units (c.f.u.)/ml. To titer the MFG retroviral stocks, 5610 5 NIH3T3 cells were infected with 1 ml of the dierent viral suspensions in presence of 8 mg/ml of polybrene. Forty-eight hours later, genomic DNAs were extracted from the con¯uent ®broblasts and 10 mg per sample were digested overnight with the restriction endonuclease XbaI. The digested DNA was then run on a 0.8% agarose gel and subjected to Southern blotting using a [a-32 P]dCTP-labelled probe speci®c to human RET. Band intensity was quanti®ed by direct comparison to a calibration curve. MFG retroviral stocks had a titer of about 5610 5 infectious particles per millilitre. Rat 1 cells were seeded on 100 mm culture plates. The following day, cells were incubated for 4 h to 7 h with 1610 6 infectious retroviral particles in presence of 8 mg/ml of polybrene. Forty-eight hours after infection, cells were trypsinized and seeded at a dilution of 1 : 10 in DMEM containing 2 mg/ml puromycin. PC12 cells were plated at 5610 5 cells per 35 mm dish 24 h before infection. Cells were incubated for 7 h with 1610 6 infectious viral particles plus polybrene, then refed with fresh medium.
RET protein analyses
RET protein analyses, as well as immunokinase assays were performed as detailed in Rossel et al. (1997) . The anti-RET rabbit polyclonal serum was raised against a peptide corresponding to the 20 amino acids of the carboxy-terminus of RET9 (Rossel et al., 1997) . Other antibodies used in this study are commercially available: agarose-conjugated anti-phosphotyrosine antibody, clone 4G10 was purchased from Upstate Biotechnology Incorporated (UBI, NY), monoclonal anti-phosphotyrosine 4G10 (UBI, NY); rabbit polyclonal anti-Shc (UBI, NY).
Shc protein analysis
NIH3T3 cells stably expressing the various RET alleles were starved overnight in medium containing 0.5% of fetal bovine serum and then lyzed as previously described (Rossel et al., 1997) . Shc proteins were immunoprecipitated with a polyclonal anti-Shc antibody (Transduction Laboratories, KI). Immunoprecipitates were subjected to sodium dodecyl sulfate (SDS)-12% polyacrylamide gel electrophoresis and transferred to a polyvinylidene di¯uoride membrane (Immobilon P, Millipore). To analyse the phosphotyrosine content of Shc, immunoblots were incubated with the anti-phosphotyrosine monoclonal antibody 4G10 (UBI, NY), then incubated with anti-mouse antibody conjugated to horse-radish peroxydase (HRP) (Amersham France, Les Ulis). The immunoreactive complexes were visualized using chemiluminescence (ECL Western blotting system, Amersham France, Les Ulis). The membranes were then stripped by incubation in stripping buer (100 mM 2-mercaptoethanol, 2% SDS, 62.5 mM Tris-HCl pH 6.8) and treated at 558C for 30 min. To study the Shc proteins, the ®lters were sequentially reacted with the polyclonal anti-Shc serum (Transduction Laboratories, KI) for 2 h at room temperature, then with biotinylated-protein A (Amersham France, Les Ulis) for 1 h and ®nally with HRP conjugated to streptavidin (Pierce, Interchim France) for 1 h. The ECL system was used for the revelation of immunoreactive bands. Two micrograms of Shc antibody were used for each immunoprecipitation experiment and the same serum was diluted at a ®nal concentration of 1 mg/ml for Western blot; biotinylated-protein A was diluted 1 : 500; streptavidin-HRP was used at a ®nal concentration of 1 mg/ml.
Transformation assay
Puromycin-selected Rat 1 cells were seeded into culture medium containing 10% FCS and 0.3% agar as described in Rossel et al. (1997) . Colonies were scored 3 weeks after plating.
Structural modelling of the RET tyrosine kinase domain
Multiple alignment of the sequences of the kinase domains of the insulin receptor (IRK), FGF receptor (FGFR1K) and RET (RETK) was carried out using the multiple alignment sequence programme CLUSTAL W (Thompson et al., 1994) . We modelled RETK by using the crystal structure of IRK (Hubbard et al., 1994) . The kinase insert regions located between residues 820 ± 847 of RETK and 1092 ± 1105 of IRK were not included in the model since their sequence homology was too low. Besides the kinase insert region, no insertions or deletions were required for a correct alignment of the sequences, and consequently the full length peptide backbone was not modi®ed. The modelling was performed using the programme O (Jones et al., 1991) and energy minimization was carried out with CHARMM23 (Brooks et al., 1983) with parameters de®ned by MacKerell and co-workers (MacKerell AD, Wiorkiewicz M, Karplus M, CHARMM23 All Hydrogen Parameter Set, Version 6.0, unpublished).
